Amneal pharmaceuticals, inc. announces the approval and launch of generic revatio® for oral suspension and generic amicar® tablets

Amneal pharmaceuticals, inc. announced that it has received final u.s. food and drug administration (fda) approval on its abbreviated new drug applications (anda) for generic versions of revatio® (sildenafil citrate) for oral suspension 10 mg/ml and amicar® (aminocaproic acid) tablets usp, 500 mg. amneal has immediately initiated commercialization activities. amneal was previously granted a competitive generic therapy (cgt) designation for its generic version ofamicar® by the fda. as the first approved application, amneal has been granted 180 days of cgt exclusivity.
AMRX Ratings Summary
AMRX Quant Ranking